RLMD logo

Relmada Therapeutics (RLMD) Company Overview

Profile

Full Name:

Relmada Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 20, 2014

Indexes:

Not included

Website:

http://www.relmada.com

Description:

Relmada Therapeutics, Inc. is a biotechnology company working at the clinical stage. They are involved in the development of chemical compounds with new versions of drugs that are designed to address unmet medical needs in the treatment of central nervous system disorders. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral medication for the treatment of depression and other potential indications. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Key Details

Price

$0.25

Market Cap

$7.67 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$3.28(+38.11% YoY)

PE Ratio

-

Annual ROE

-115.74%

Annual Debt To Equity

0.00

Beta

-0.17

Events Calendar

Earnings

Next earnings date:

Mar 19, 2025

Recent quarterly earnings:

Nov 7, 2024

Recent annual earnings:

Mar 19, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 30, 2019

Analyst ratings

Recent major analysts updates

Dec 5, 24 Mizuho
Neutral
Dec 4, 24 Leerink Partners
Market Perform
Jun 5, 24 Goldman Sachs
Sell
Jun 15, 23 Mizuho
Buy
Jan 23, 23 SVB Leerink
Outperform
Oct 14, 22 Guggenheim
Neutral
Oct 14, 22 Goldman Sachs
Neutral
Oct 13, 22 Oppenheimer
Perform
Sep 23, 22 Goldman Sachs
Buy
Sep 6, 22 Guggenheim
Buy

Screeners with RLMD included

Growing Shares Outstanding
Stocks cheaper than 1 dollar
US stocks
Stocks below SMA 200
Stocks recommended to hold
Stocks below analysts price target
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$0.25
RLMD price is $0.25

Price All-time High

$74.40
RLMD price is currently -99.66% below its historical high of $74.40

Price Analysts Target

$1.00
RLMD price is currently -74.58% lower than the consensus analysts' forecast

Price Today Change

-5.85%
RLMD price is down -5.85% today

Price YTD Change

-50.16%
RLMD price is down -50.16% since January 1st

Price 3-Year Change

-98.77%
RLMD price is down -98.77% over the past 3 years

Market cap

Market Cap

$7.67 M
RLMD market capitalization is $7.67 million

Market Cap 3-Year Change

-98.66%
RLMD market capitalization is down -98.66% over the past 3 years

Market Cap All-time High

$1.06 B
RLMD market capitalization is currently -99.28% below its historical high of $1.06 billion

Market Cap Sector Rank

15.72%
RLMD market capitalization is higher than 15.72% of companies in Healthcare sector

Technical

Beta

-0.17
RLMD beta is -0.17

200-day SMA

$2.35
RLMD price is currently -89.18% below its 200-day simple moving average

14-day RSI

29.41
RLMD 14-day relative strength index is 29.41

30-day Relative Volume

0.96
RLMD 30-day relative volume is 0.96

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
RLMD annual revenue value is unknown

Annual Revenue Analysts Estimate

-
RLMD annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
RLMD annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
RLMD annual revenue is unknown

Profit

Annual Gross Profit

-
RLMD annual gross profit value is unknown

Annual Gross Margin

-
RLMD annual gross profit margin value is unknown

Annual Operating Profit

-$103.70 M
RLMD annual operating income is -$103.70 million

Annual Operating Margin

-
RLMD annual operating profit margin value is unknown

Annual Net Income

-$98.79 M
RLMD annual net profit is -$98.79 million

Annual Net Margin

-
RLMD annual net profit margin value is unknown

EPS

Annual EPS

-$3.28
RLMD annual earnings per share is -$3.28

Annual EPS Analysts Estimate

-$1.72
RLMD annual earnings per share is currently +90.70% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+38.11%
RLMD annual earnings per share is up +38.11% year-on-year

Annual EPS Sector Rank

31.26%
RLMD annual earnings per share is higher than 31.26% of companies in Healthcare sector

ROA & ROE

Annual ROA

-101.27%
RLMD annual return on assets is -101.27%

Annual ROE

-115.74%
RLMD annual return on equity is -115.74%

EBIT & EBITDA

Annual EBIT

-$103.70 M
RLMD annual earnings before interest & taxes is -$103.70 million

Annual EBITDA

-$103.70 M
RLMD annual EBITDA is -$103.70 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
RLMD price to earnings ratio value is unknown

PE Ratio Sector Rank

-
RLMD price to earnings ratio is unknown

PB Ratio

PB Ratio

0.16
RLMD price to book ratio is 0.16

PB Ratio Sector Rank

18.73%
RLMD price to book ratio is higher than 18.73% of companies in Healthcare sector

PS Ratio

PS Ratio

-
RLMD price to sales ratio value is unknown

PS Ratio Sector Rank

-
RLMD price to sales ratio is unknown

Enterprise value

Enterprise Value

$6.19 M
RLMD enterprise value is $6.19 million

Enterprise Value Sector Rank

19.92%
RLMD enterprise value is higher than 19.92% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.07
RLMD EV/EBITDA is -0.07

EV/EBITDA Sector Rank

64.01%
RLMD EV/EBITDA is higher than 64.01% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

8.00
RLMD annual current ratio is 8.00

Annual Quick Ratio

-
RLMD annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
RLMD annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
RLMD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
RLMD piotroski f-score value is unknown

Altman Z-Score

-
RLMD altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$97.55 M
RLMD annual total assets is $97.55 million

Annual Non Current Assets

$43.10 K
RLMD annual long term assets is $43.10 thousand

Annual Current Assets

$97.51 M
RLMD annual total current assets is $97.51 million

Annual Cash & Cash Equivalents

$4.09 M
RLMD annual cash & cash equivalents is $4.09 million

Equity

Annual Book Value

$85.36 M
RLMD annual book value is $85.36 million

Annual Working Capital

$85.31 M
RLMD annual working capital is $85.31 million

Liabilities

Annual Total Liabilities

$12.19 M
RLMD annual total liabilities is $12.19 million

Annual Total Long Term Liabilities

$0.00
RLMD annual total long term liabilities is $0.00

Annual Current Liabilities

$12.19 M
RLMD annual total current liabilities is $12.19 million

Annual Accounts Payable

$3.51 M
RLMD annual accounts payable is $3.51 million

Debt

Annual Total Debt

$0.00
RLMD annual total debt is $0.00

Annual Total Debt 1-Year Change

0%
RLMD {parameterFullLabel} has remained unchanged year-on-year

Annual Long Term Debt

-
RLMD annual long term debt value is unknown

Annual Short Term Debt

-
RLMD annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$103.70 M
RLMD annual total expenses is $103.70 million

Annual Operating Expenses

$103.70 M
RLMD annual total operating expenses is $103.70 million

Annual Cost Of Goods Sold

-
RLMD annual cost of goods sold value is unknown

Annual SGA

$48.89 M
RLMD annual SGA is $48.89 million

Annual D&A

-
RLMD annual depreciation & amortization value is unknown

Annual Interest Expense

-
RLMD annual interest expense value is unknown

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$51.66 M
RLMD annual cash flow from operations is -$51.66 million

Annual CFO 1-Year Change

+50.23%
RLMD annual cash flow from operations is up +50.23% year-on-year

Annual CFI

$50.45 M
RLMD annual cash flow from investing activities is $50.45 million

Annual CFI 1-Year Change

+155.67%
RLMD annual cash flow from investing activities is up +155.67% year-on-year

Annual CFF

-$98.50 K
RLMD annual cash flow from financing activities is -$98.50 thousand

Annual CFF 1-Year Change

-100.22%
RLMD annual cash flow from financing activities is down -100.22% year-on-year

Free CashFlow

Annual FCF

-$51.66 M
RLMD annual free cash flow is -$51.66 million

Annual FCF 1-Year Change

+50.23%
RLMD annual free cash flow is up +50.23% year-on-year

CAPEX

Annual CAPEX

-
RLMD annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
RLMD annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

STSS logo
Sharps Technology (STSS)
AYTU logo
Aytu BioPharma (AYTU)
TRAW logo
Traws Pharma (TRAW)
OSA logo
ProSomnus (OSA)
ADXN logo
Addex Therapeutics Ltd (ADXN)
INDP logo
Indaptus Therapeutics (INDP)
Adagio Medical Holdings (ADGM)
POAI logo
Predictive Oncology (POAI)
MHUA logo
Meihua International Medical Technologies Co (MHUA)

FAQ

  • What is the ticker symbol for Relmada Therapeutics?
  • Does Relmada Therapeutics pay dividends?
  • What sector is Relmada Therapeutics in?
  • What industry is Relmada Therapeutics in?
  • What country is Relmada Therapeutics based in?
  • When did Relmada Therapeutics go public?
  • Is Relmada Therapeutics in the S&P 500?
  • Is Relmada Therapeutics in the NASDAQ 100?
  • Is Relmada Therapeutics in the Dow Jones?
  • When was Relmada Therapeutics's last earnings report?
  • When does Relmada Therapeutics report earnings?
  • Should I buy Relmada Therapeutics stock now?

What is the ticker symbol for Relmada Therapeutics?

The ticker symbol for Relmada Therapeutics is NASDAQ:RLMD

Does Relmada Therapeutics pay dividends?

No, Relmada Therapeutics does not pay dividends

What sector is Relmada Therapeutics in?

Relmada Therapeutics is in the Healthcare sector

What industry is Relmada Therapeutics in?

Relmada Therapeutics is in the Biotechnology industry

What country is Relmada Therapeutics based in?

Relmada Therapeutics is headquartered in United States

When did Relmada Therapeutics go public?

Relmada Therapeutics's initial public offering (IPO) was on June 20, 2014

Is Relmada Therapeutics in the S&P 500?

No, Relmada Therapeutics is not included in the S&P 500 index

Is Relmada Therapeutics in the NASDAQ 100?

No, Relmada Therapeutics is not included in the NASDAQ 100 index

Is Relmada Therapeutics in the Dow Jones?

No, Relmada Therapeutics is not included in the Dow Jones index

When was Relmada Therapeutics's last earnings report?

Relmada Therapeutics's most recent earnings report was on Nov 7, 2024

When does Relmada Therapeutics report earnings?

The next expected earnings date for Relmada Therapeutics is Mar 19, 2025

Should I buy Relmada Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions